Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Research ArticleIllustrated Post

[68Ga]Ga-FAPI-46 PET for Visualization of Postinfarction Renal Fibrosis

Lena M. Unterrainer, Anthony E. Sisk, Johannes Czernin, Brian M. Shuch, Jeremie Calais and Masatoshi Hotta
Journal of Nuclear Medicine October 2023, 64 (10) 1660-1661; DOI: https://doi.org/10.2967/jnumed.123.265640
Lena M. Unterrainer
1Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, California;
2Department of Nuclear Medicine, University Hospital, LMU Munich, Munich, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anthony E. Sisk Jr.
3Department of Pathology, David Geffen School of Medicine, UCLA, Los Angeles, California;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Johannes Czernin
1Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, California;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Brian M. Shuch
4Department of Urology, UCLA, Los Angeles, California; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jeremie Calais
1Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, California;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Masatoshi Hotta
1Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, California;
5Division of Nuclear Medicine, Department of Radiology, National Center for Global Health and Medicine, Tokyo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Fibroblast activation protein (FAP)–targeted PET imaging is promising for cancers with a high content of cancer-associated fibroblasts (1,2). However, FAP is also expressed by activated fibroblasts involved in multiple fibroinflammatory nononcologic conditions. FAP is involved in remodeling processes by stimulating fibrosis and extracellular matrix remodeling after an infarction. After myocardial infarction, FAP inhibitor (FAPI) PET imaging can show the activated fibroblasts (3) in the territory of the occluded coronary artery (4). In the early stage of renal fibrosis, fibroblasts accumulate in the renal parenchyma. Preliminary experience with FAPI PET quantification of renal fibrosis has been reported (5).

Here, we report the case of an 83-y-old man with clear cell renal cell carcinoma of the left kidney with gross hematuria requiring blood transfusions and an emergency embolization of the left renal artery (Fig. 1). Subsequently nephrectomy was planned, and the patient preoperatively underwent both [18F]FDG (26 d after embolization) and [68Ga]Ga-FAPI-46 PET/CT (67 d after embolization) as part of the exploratory study (NCT04147494), which was approved by the institutional review board. The primary tumor had a slight hypermetabolism at its periphery ([18F]FDG SUVmax, 5.9) without increased FAP uptake (FAPI SUVmax, 2.0). [68Ga]Ga-FAPI-46 PET/CT showed increased uptake in the embolization area in the lower-pole left kidney parenchyma (SUVmax, 4.1 vs. 1.7 in the normal parenchyma). [18F]FDG PET/CT showed significantly decreased uptake at the infarction site (SUVmax, 1.9 vs. 4.8 in the normal parenchyma). The FAP immunohistochemistry staining performed on the nephrectomy tissue showed an increased FAP expression in the ischemic areas that included reactive fibroblasts, whereas the primary tumor had no significant FAP expression. The corresponding hematoxylin and eosin staining showed the ischemic stromal cells and adjacent tumor. Our findings suggest that [68Ga]Ga-FAPI-46 PET/CT molecular imaging can show FAP expression in fibrotic renal tissue and may represent a valuable biomarker for remodeling processes after infarction of the kidney.

FIGURE 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 1.

(Row 1) Preembolization angiography with contrast extravasation of lower branch of left renal artery and tumor-associated neovasculature (left panel, circle) and postembolization angiography showing occlusion of arterial vessels (right panel, circle). (Rows 2 and 3, from left to right) Maximum-intensity-projection, CT, PET, and PET/CT images obtained with [68Ga]Ga-FAPI-46 and [18F]FDG. Blue arrows denote primary tumor, and red arrows denote embolization area. (Row 4) Immunohistochemistry staining (left panel) and hematoxylin and eosin staining (right panel) (scale bars = 25 μm).

DISCLOSURE

No potential conflict of interest relevant to this article was reported.

Footnotes

  • Published online Jun. 15, 2023.

  • Guest Editor: Todd Peterson, Vanderbilt University

  • © 2023 by the Society of Nuclear Medicine and Molecular Imaging.

REFERENCES

  1. 1.↵
    1. Loktev A,
    2. Lindner T,
    3. Mier W,
    4. et al
    . A tumor-imaging method targeting cancer-associated fibroblasts. J Nucl Med. 2018;59:1423–1429.
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    1. Lindner T,
    2. Loktev A,
    3. Altmann A,
    4. et al
    . Development of quinoline-based theranostic ligands for the targeting of fibroblast activation protein. J Nucl Med. 2018;59:1415–1422.
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    1. Varasteh Z,
    2. Mohanta S,
    3. Robu S,
    4. et al
    . Molecular imaging of fibroblast activity after myocardial infarction using a 68Ga-labeled fibroblast activation protein inhibitor, FAPI-04. J Nucl Med. 2019;60:1743–1749.
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    1. Notohamiprodjo S,
    2. Nekolla SG,
    3. Robu S,
    4. et al
    . Imaging of cardiac fibroblast activation in a patient after acute myocardial infarction using 68Ga-FAPI-04. J Nucl Cardiol. 2022;29:2254–2261.
    OpenUrl
  5. 5.↵
    1. Conen P,
    2. Pennetta F,
    3. Dendl K,
    4. et al
    . [68Ga] Ga-FAPI uptake correlates with the state of chronic kidney disease. Eur J Nucl Med Mol Imaging. 2022;49:3365–3372.
    OpenUrl
  • Received for publication March 1, 2023.
  • Revision received March 24, 2023.
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 64 (10)
Journal of Nuclear Medicine
Vol. 64, Issue 10
October 1, 2023
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Complete Issue (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
[68Ga]Ga-FAPI-46 PET for Visualization of Postinfarction Renal Fibrosis
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
[68Ga]Ga-FAPI-46 PET for Visualization of Postinfarction Renal Fibrosis
Lena M. Unterrainer, Anthony E. Sisk, Johannes Czernin, Brian M. Shuch, Jeremie Calais, Masatoshi Hotta
Journal of Nuclear Medicine Oct 2023, 64 (10) 1660-1661; DOI: 10.2967/jnumed.123.265640

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
[68Ga]Ga-FAPI-46 PET for Visualization of Postinfarction Renal Fibrosis
Lena M. Unterrainer, Anthony E. Sisk, Johannes Czernin, Brian M. Shuch, Jeremie Calais, Masatoshi Hotta
Journal of Nuclear Medicine Oct 2023, 64 (10) 1660-1661; DOI: 10.2967/jnumed.123.265640
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • DISCLOSURE
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Dual Role for l-[Methyl-11C]-Methionine PET in Acromegaly: Confirming Remission and Detecting Recurrence
  • C-X-C Motif Chemokine Receptor 4–Directed Scintigraphy of Multiple Myeloma Using [99mTc]Tc-PentixaTec
  • Somatostatin Receptor Antagonists as a Theranostic Option in Iodine-Refractory Thyroid Carcinoma
Show more Illustrated Post

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire